360° Coverage : Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at...

2 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos Tweets

 
 
 

48 weeks ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 
Update
2

Tweets

 
 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Wild berry extract booster for pancreatic cancer drug
London, Sep 18 (IANS) A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals new research.
 
 
Male peacock doesn't sacrifice much to woo his lady
London, Sep 18 (IANS) The magnificent plumage of the peacock may not be quite the sacrifice for love that it appears to be, researchers at the University of Leeds have found.
 
 
Babies master words differently as they grow
Washington, Sep 18 (IANS) Toddlers learn words differently as they grow and there also is a limit as to how many words they can learn each day, says a study.
 
 
Ocean acidification 'hammering' coral growth
Washington, Sep 18 (IANS) In a disturbing trend, a team of researchers has documented that coral growth rates have plummeted 40 percent since the mid-1970s.
 
 
 

Latest from the Network

Wild berry extract booster for pancreatic cancer drug
London, Sep 18 (IANS) A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals new research. The team at King's College Hospital...
Read more on Apple Balla
 
Male peacock doesn't sacrifice much to woo his lady
London, Sep 18 (IANS) The magnificent plumage of the peacock may not be quite the sacrifice for love that it appears to be, researchers at the University of Leeds have found. A team filmed five Indian peacocks using...
Read more on Apple Balla
 
Babies master words differently as they grow
Washington, Sep 18 (IANS) Toddlers learn words differently as they grow and there also is a limit as to how many words they can learn each day, says a study. These findings may help parents enhance their children's...
Read more on Apple Balla
 
Scottish referendum: How the Scots changed our world forever
London, Sep 18 (IANS) As the Scottish referendum gets underway in Britain Thursday, there are plenty of ways to celebrate the country's contribution to the present day world, The Independent reported. Some of these are...
Read more on Politics Balla
 
Ocean acidification 'hammering' coral growth
Washington, Sep 18 (IANS) In a disturbing trend, a team of researchers has documented that coral growth rates have plummeted 40 percent since the mid-1970s. The scientists working on Carnegie Mellon University's...
Read more on Apple Balla
 
Are YouTube, Facebook, Twitter hiding female abuse data?
New York, Sep 18 (IANS) Are YouTube, Facebook and Twitter hiding responses related to female harassment? If we believe a new study, the social media firms are not faring well on publishing abuse-reporting data. The...
Read more on Celebrity Balla
 
Afridi urges team-mates to rally for World Cup
Karachi, Sep 18 (IANS) Veteran Pakistan all-rounder Shahid Afridi urged his team-mates to back one another if they were to win the 2015 World Cup in Australia and New Zealand and end the country's 23-year long wait for...
Read more on Sport Balla
 
Chronic medical condition no bar to space travel
New York, Sep 18 (IANS) Nurse a desire to travel in a space taxi but wary of the space flight and its impact on high blood pressure or diabetes? Take heart. The aerospace medicine group at the University of Texas'...
Read more on Apple Balla
 
Fear of loss drives entrepreneurs
New York, Sep 18 (IANS) Loss aversion or fear of losing one's salary at a full-time job, along with its prestige is what drives most entrepreneurs and not a love of risk. According to a study, entrepreneurs are also...
Read more on Celebrity Balla
 
Iran sentences dancing youths to jail, 91 lashes
Tehran, Sep 18 (IANS) A group of Iranian youths, who released a video on YouTube dancing to the popular song "Happy" by American singer-songwriter Pharrell Williams, has been sentenced to six months in jail accompanied...
Read more on Celebrity Balla